Influence of Ageing on the Pharmacology, Efficacy and Safety of Oral Targeted Therapies for Inflammatory Bowel Disease: Focus on Janus Kinase (JAK) Inhibitors and Sphingosine-1-Phosphate (S1P) Receptor Modulators.

Conflict statement: Declarations. Conflict of interest: Luc J.J. Derijks has served as a speaker for AbbVie, Celltrion, Janssen-Cilag and Takeda and has developed continuing education materials for Ferring, all outside the submitted work. Fatma Karapinar-Çarkit has no conflicts of interest that are directly relevant to the content of this article. Zlatan Mujagić received grants from ZonMw, Niels Stensen Fellowship, MLDS, Top consortium for Knowledge and Innovation (TKI) and Galapagos; advisory board fees from Johnson & Johnson, Eli Lilly and Pfizer (paid to host institution)l and speaker’s fees from Friso-Friesland Campina, Galapagos, Eli Lilly and Takeda (paid to host institution), all outside the submitted work. Rob J. van Marum has no conflicts of interest that are directly relevant to the content of this article. Marieke J. Pierik has received grants from Falk Pharma, the European Commission, ZonMw, Takeda, Johnson & Johnson and AbbVie and non-financial support from Falk Pharma, Takeda, Johnson & Johnson, AbbVie, Ferring, Immunodiagnostics and MSD, all outside the submitted work. Ethics approval: Not applicable. Consent to participate: Not applicable. Consent for publication: Not applicable. Availability of data and material: Not applicable. Code availability: Not applicable. Author contributions: LD accepted the invitation and wrote the manuscript. All authors contributed to the drafting and critical revision of the manuscript and approved the final version of this manuscript.